SGMT
HEALTHCARESagimet Biosciences Inc. Series A Common Stock
What's Moving SGMT Today?
No stock-specific AI insight has been generated for SGMT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.06
Fundamentals
Trading
SGMT News
20 articles- Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Jun 23, 2026
- Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom FisherYahoo Finance·Jun 4, 2026
- Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHYahoo Finance·May 27, 2026
- Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to TradeYahoo Finance·May 21, 2026
- Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQYahoo Finance·May 13, 2026
- Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo Finance·May 12, 2026
- Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoYahoo Finance·May 11, 2026
- Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?Yahoo Finance·May 5, 2026
- Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?Yahoo Finance·May 5, 2026
- Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M RaiseMarketbeat·May 1, 2026
- Why Sagimet Biosciences Stock Is Soaring TodayMotley Fool·Apr 27, 2026
- Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion PlansAdvfn·Apr 27, 2026
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockYahoo Finance·Apr 27, 2026
- Sagimet Biosciences Provides Strategic and Corporate UpdatesYahoo Finance·Apr 27, 2026
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswire Inc.·Apr 20, 2026
- Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 6, 2026
- Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 ResultsYahoo Finance·Mar 25, 2026
- Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 11, 2026
- Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.Marketbeat·Mar 1, 2026
- Sagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
52-Week Range
$7.06
Fundamentals
Trading
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing breakthrough treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company is actively advancing its lead therapeutic candidate through various clinical trial phases, employing cutting-edge mechanisms designed to enhance patient outcomes. Backed by a robust management team and a strong intellectual property portfolio, Sagimet is strategically positioned to capitalize on the growing market demand for effective metabolic disease therapies, making it an attractive investment proposition for institutional investors in the dynamic biotech sector.